Author

Ron Firestein

Hudson Institute of Medical ResearchORCID 0000-0002-5255-1838Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Approach:experimental assay· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2

Frequent Co-Authors

Claire Xin SuniD· 4 shared Isaac B. WoodhouseiD· 2 shared Pouya FaridiiD· 2 shared Tima ShamekhiiD· 2 shared Timothy N. PhoenixiD· 2 shared Aaminah KhaniD· 1 shared Abby GrieriD· 1 shared Alan G. MackayiD· 1 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Claire Xin SunORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Combination of ALK2 and cholesterol targeting agents exploits linked genetic and metabolic dependencies in diffuse midline glioma

Rebecca Rogers, Alan G. Mackay, Yura Grabovska, Diana Carvalho, Claire Dobinson, Anna Burford, Valeria Molinari, Rita Pereira, Laura Bevington, Ruth Ruddle, Josephine Nkrumah, Haider Tari, Jiin Song, Drenusha Sejdiu, Nicole Chew, , Chris Jones

This study identifies a combinatorial strategy using ALK2 inhibitors and statins to target metabolic dependencies in diffuse midline glioma.

bioRxiv · Sep 23, 2026 · PreprintCancer Biology

Chromatin remodeling with combined FACT and BET inhibition disrupts oncogenic transcription in Diffuse Midline Glioma

Holly Holliday, Aaminah Khan, Anahid Ehteda, Hieu Nguyen, Samuel E. Ross, Nisitha Jayatilleke, Anjana Gopalakrishnan, Eyden Wang, Yolanda Colino‐Sanguino, Daisy Kavanagh, Xinyi Guo, Jie Liu, David Lawrence, Claire Xin Sun, Rebecca J. Lehmann, , David Simon Ziegler

This study shows that combining FACT and BET inhibition disrupts oncogenic transcription and extends survival in Diffuse Midline Glioma models.

Science Translational Medicine · Jan 14, 2026Peer-reviewedCancer Biology

Resource: A Compendium of HLA-Type and Expression in Pediatric Cancer Models

Yu Guan, Ishika Mahajan, Vikesh Ajith, Dingyin Sun, Isaac B. Woodhouse, Tima Shamekhi, Pouya Faridi, Ron Firestein, Claire Xin Sun

The paper compiles HLA typing and expression data for 287 pediatric cancer cell lines to support immunotherapy research and personalized treatment development.

iScience · Oct 29, 2025Peer-reviewedCancer Biology

Integrative Multi-Omics Analysis Identifies Nuclear Factor I as a Key Driver of Dysregulated Purine Metabolism in DIPG

Ian Mersich, Sunny Congrove, Matthew J. Horchar, Román Cáceres, Ranjithmenon Muraleedharan, Janki M. Desai, Pankaj B. Desai, Larry Sallans, Julie A. Reisz, Abby Grier, Matthew R. Hass, Omer Donmez, Cailing Yin, Matthew T. Weirauch, Leah Claire Kottyan, , Biplab Dasgupta

This study identifies nuclear factor I (NFI) as a driver of dysregulated purine metabolism in DIPG, showing that targeting ATIC reduces tumor progression in mice.

bioRxiv · May 21, 2025 · PreprintCancer Biology

H3K27M Mutation Reshapes the Antigenic Landscape in Diffuse Midline Glioma

Tima Shamekhi, Bijun Zeng, Claire Xin Sun, Paul M Daniel, Terry C.C. Lim Kam Sian, Gabriel Gonçalves, Grace Huang, Farnaz Fahimi, Nivedhitha Selvakumar, Erwin Tanuwidjaya, Isaac B. Woodhouse, Bettina Kritzer, Ralf B. Schittenhelm, Roberta Mazzieri, Jason E. Cain, , Pouya Faridi

This study identifies six immunogenic peptides in diffuse midline glioma (DMG) linked to the H3K27M mutation, offering potential targets for T cell-based immunotherapy.

bioRxiv · Apr 7, 2025 · PreprintCancer Biology